Coya Therapeutics Inc COYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
-
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
-
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
-
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Trading Information
- Previous Close Price
- $4.85
- Day Range
- $4.76–5.01
- 52-Week Range
- $3.71–7.75
- Bid/Ask
- $4.51 / $5.00
- Shares Outstanding
- 23.46M
- Market Cap
- $115.18M
- Volume/Avg
- 95,511 / 168,475
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.coyatherapeutics.com
Valuation
|
Metric
|
COYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.66 |
Price/Sales | 12.18 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
COYA
|
|---|---|
Quick Ratio | 12.29 |
Current Ratio | 13.40 |
Interest Coverage | — |
Quick Ratio
COYA
Profitability
|
Metric
|
COYA
|
|---|---|
Return on Assets (Normalized) | −37.86% |
Return on Equity (Normalized) | −42.85% |
Return on Invested Capital (Normalized) | −42.85% |
Return on Assets
COYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|C#%<BY | LOCK|xg&r@ | $128B | |||
| Moderna Inc
MRNA
| LOCK|LvffQ# | LOCK|>z | $78B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lg$&?Y | LOCK|?Pwd# | $76B | |||
| argenx SE ADR
ARGX
| LOCK|^%^P&%V | LOCK|%bs | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|z^<d@%! | LOCK|?S | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|WFgpz?? | LOCK|yCT%j | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|y#GHd#W | LOCK|WMBWw | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>?kN#t | LOCK|MP | $24B | |||
| Incyte Corp
INCY
| LOCK|Hv>w>G^ | LOCK|l^ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&^?&L@N | LOCK|B!! | $15B |
United States